Sponsor

NeuroDerm Ltd.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name NeuroDerm Ltd. appears in 13 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials13
Recruiting shown0
Roles1
SourceClinicalTrials.gov
Advertisement

Clinical trials

13 shown
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor FluctuationsNCT04006210 · lead sponsor · 2019-09-30
ACTIVE_NOT_RECRUITING
A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral SuspensionNCT03462043 · lead sponsor · 2018-04-10
WITHDRAWN
A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor FluctuationsNCT02782481 · lead sponsor · 2016-08-01
WITHDRAWN
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's DiseaseNCT02726386 · lead sponsor · 2016-05-04
ACTIVE_NOT_RECRUITING
A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's DiseaseNCT02577523 · lead sponsor · 2015-12-29
COMPLETED
A Sequential Two-Part, Open-Label Study in Healthy Male and Female SubjectsNCT02604914 · lead sponsor · 2015-05-29
COMPLETED
A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)NCT02486432 · lead sponsor · 2015-04-01
COMPLETED
A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease PatientsNCT02096601 · lead sponsor · 2014-08-11
COMPLETED
A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease PatientsNCT01883505 · lead sponsor · 2014-01-06
COMPLETED
A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) PatientsNCT01725802 · lead sponsor · 2012-12-16
COMPLETED
Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy VolunteersNCT01486628 · lead sponsor · 2012-04-30
COMPLETED
A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease PatientsNCT01229332 · lead sponsor · 2011-01-01
COMPLETED
Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611NCT01103011 · lead sponsor · 2010-04-01
COMPLETED

Drugs studied in this sponsor's trials

3 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing NeuroDerm Ltd. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo4
entacapone2
carbidopa1
placebo RxCUI 8375 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials entacapone RxCUI 60307 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials carbidopa RxCUI 2019 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor13
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.